<SEC-DOCUMENT>0001193125-25-005052.txt : 20250113
<SEC-HEADER>0001193125-25-005052.hdr.sgml : 20250113
<ACCEPTANCE-DATETIME>20250113090824
ACCESSION NUMBER:		0001193125-25-005052
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250108
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250113
DATE AS OF CHANGE:		20250113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apellis Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001492422
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				271537290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38276
		FILM NUMBER:		25525065

	BUSINESS ADDRESS:	
		STREET 1:		100 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-977-5700

	MAIL ADDRESS:	
		STREET 1:		100 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d885806d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:apls="http://www.apellis.com/20250108" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-280">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-01-08_to_2025-01-08">0001492422</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="apls-20250108.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-01-08_to_2025-01-08"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001492422</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-08</xbrli:startDate> <xbrli:endDate>2025-01-08</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-291">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-01-08_to_2025-01-08" format="ixt:datemonthdayyearen" id="ixv-292">January 8, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-293">Apellis Pharmaceuticals, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-01-08_to_2025-01-08" format="ixt-sec:stateprovnameen" id="ixv-294">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-295">001-38276</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-296">27-1537290</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-297">100 Fifth Avenue</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-298">Waltham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-299">MA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-300">02451</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-301">(617)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-302">977-5700</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-style:italic">see</span> General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-01-08_to_2025-01-08" format="ixt-sec:boolballotbox" id="ixv-303">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-01-08_to_2025-01-08" format="ixt-sec:boolballotbox" id="ixv-304">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-01-08_to_2025-01-08" format="ixt-sec:boolballotbox" id="ixv-305">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-01-08_to_2025-01-08" format="ixt-sec:boolballotbox" id="ixv-306">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-307">Common Stock</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-308">APLS</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-08_to_2025-01-08" format="ixt-sec:exchnameen" id="ixv-309">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-01-08_to_2025-01-08" format="ixt-sec:boolballotbox" id="ixv-310">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;2.02 Results of Operations and Financial Condition. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;13, 2025, Apellis Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing preliminary unaudited total U.S. net product revenues and net product revenues for SYFOVRE and EMPAVELI for the fourth quarter and full year ended December&#160;31, 2024 and its cash and cash equivalents as of December&#160;31, 2024. The full text of the press release issued by the Company in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s U.S. net product revenues and cash figures are preliminary and unaudited, represent management&#8217;s estimate as of the date of this report and are subject to completion of the Company&#8217;s financial closing procedures. The Company&#8217;s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the Company&#8217;s net product revenues or cash figures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Election of Keli Walbert to the Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2025, the Board of Directors (the &#8220;Board&#8221;) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Keli Walbert to the Board as a Class&#160;II director to serve until the Annual Meeting of Stockholders to be held in 2025 or until her successor has been duly elected and qualified or until her earlier death, resignation or removal. The Board has determined that Ms.&#160;Walbert is &#8220;independent&#8221; as contemplated by the Nasdaq Stock Market rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&#160;Walbert will be compensated in the same manner as the Company&#8217;s other <span style="white-space:nowrap">non-employee</span> directors. Information concerning the current compensation of the Company&#8217;s directors is set forth in the Company&#8217;s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on April&#160;26, 2024. Accordingly, upon her election to the Board, Ms.&#160;Walbert was granted under the Company&#8217;s 2017 Stock Incentive Plan (i)&#160;an option to purchase 15,388 shares of the Company&#8217;s common stock at an exercise price equal to $33.00 per share, the closing price of the Company&#8217;s common stock on the date of grant, which option will vest with respect to <span style="white-space:nowrap">one-third</span> of the shares underlying such option on each of the first, second and third anniversaries of the date of grant, and (ii)&#160;restricted stock units (&#8220;RSUs&#8221;) for 9,090 shares of the Company&#8217;s common stock, which RSUs will vest in full on the first anniversary of the date of grant, although Ms.&#160;Walbert may choose to defer vesting of the RSUs until after termination of her service, in each case, subject to Ms.&#160;Walbert&#8217;s continued service. In the event of a change in control of the Company, the vesting schedule of the option and the RSUs will accelerate in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&#160;Walbert, 58, most recently served as Executive Vice President, U.S. Commercial for Horizon Therapeutics plc, a biopharmaceutical company (&#8220;Horizon&#8221;), where she had numerous roles of increasing responsibility, from January 2019 until Horizon&#8217;s acquisition by Amgen Inc. in October 2023, including driving the U.S. commercial strategy and organizational development for Horizon&#8217;s portfolio of rare disease medicines. Before joining Horizon, Ms.&#160;Walbert held leadership roles at AbbVie Inc., the American Medical Association, Abbott Laboratories and UnitedHealthcare. Ms.&#160;Walbert has a B.A. from the University of Louisville, and a M.S. from Northwestern University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between Ms.&#160;Walbert and any other persons pursuant to which she was elected as a director. Ms.&#160;Walbert has no family relationships with any of the Company&#8217;s directors or executive officers. There are no transactions and no proposed transactions between Ms.&#160;Walbert and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&#160;Walbert has entered into an indemnification agreement with the Company, a form of which was filed as Exhibit 10.7 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1/A</span> filed with Securities and Exchange Commission on October&#160;27, 2017. Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Ms.&#160;Walbert for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by her in any action or proceeding arising out of her service as a director of the Company. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Departure of Adam Townsend </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;10, 2025, the Company and Adam Townsend mutually agreed that Mr.&#160;Townsend will resign as the Company&#8217;s Chief Operating Officer effective as of February&#160;21, 2025 (the &#8220;Separation Date&#8221;). Mr.&#160;Townsend entered into a letter agreement with the Company (the &#8220;Separation Agreement&#8221;) effective as of January&#160;10, 2025 (the &#8220;Agreement Date&#8221;), pursuant to which Mr.&#160;Townsend will resign from his position as Chief Operating Officer of the Company and from all other positions he holds as an officer or employee of the Company, effective as of the Separation Date. During the period between the Agreement Date and the Separation Date (the &#8220;Transition Period&#8221;), Mr.&#160;Townsend has agreed to continue to serve as Chief Operating Officer. During the Transition Period, Mr.&#160;Townsend will continue to receive his base salary as in effect as of the Agreement Date and will remain eligible to participate in Company benefit plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Separation Agreement, Mr.&#160;Townsend is entitled to receive the following payments and benefits: (i)&#160;a lump sum payment in an aggregate amount equivalent to nine months of Mr.&#160;Townsend&#8217;s base salary in effect on the Separation Date, less all applicable taxes and withholdings, (ii)&#160;company contributions to the cost of health care continuation under the Consolidated Omnibus Budget Reconciliation Act until the earlier of nine months following the Separation Date and the date on which Mr.&#160;Townsend and his eligible dependents, if applicable, become eligible for group health insurance coverage through a new employer, and (iii)&#160;Mr.&#160;Townsend&#8217;s 2024 bonus, if it has not been paid by the Separation Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement also provides for, among other things, a release of claims by Mr.&#160;Townsend, <span style="white-space:nowrap">non-disparagement</span> obligations applicable to Mr.&#160;Townsend and <span style="white-space:nowrap">non-disparagement</span> obligations applicable to the Company, and a covenant not to sue applicable to Mr.&#160;Townsend. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of such agreement. The Company expects to file a copy of the Separation Agreement as an exhibit to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d885806dex991.htm">Press Release dated January&#160;13, 2025 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Apellis Pharmaceuticals, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;13, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Timothy Sullivan</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Timothy Sullivan</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d885806dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g885806g33r93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Apellis Highlights Commercial Growth and Strategic Priorities at 43<SUP
STYLE="font-size:75%; vertical-align:top">rd</SUP> Annual J.P. Morgan Healthcare Conference </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Reports $709</I><I></I><I>&nbsp;million in
preliminary</I><I><SUP STYLE="font-size:75%; vertical-align:top">1</SUP></I><I> full-year 2024 U.S. net product revenues</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>$611</I><I></I><I>&nbsp;million in
SYFOVRE</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I><I> U.S. net product revenues, including $167</I><I></I><I>&nbsp;million in 4Q 2024</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>$98</I><I></I><I>&nbsp;million in
EMPAVELI</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I><I> U.S. net product revenues, including $23</I><I></I><I>&nbsp;million in 4Q 2024</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expects submission of EMPAVELI sNDA for C3G and primary <FONT STYLE="white-space:nowrap">IC-MPGN</FONT> in
early 2025; U.S. launch anticipated in 2H 2025, if approved</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Plans initiation of Phase 3 studies of pegcetacoplan in two additional nephrology indications in 2H 2025</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Adam Townsend, chief operating officer, to depart Apellis in February; David Acheson named executive vice
president of commercial</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Maintained strong financial position with <FONT STYLE="white-space:nowrap">year-end</FONT> cash of
approximately $410</I><I></I><I>&nbsp;million; projected revenues and cash expected to be sufficient to fund operations to profitability</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WALTHAM, Mass.,&nbsp;January 13, 2025 (GLOBE NEWSWIRE) &#150; Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product
revenues for the fourth quarter and the full year 2024 for SYFOVRE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pegcetacoplan injection) for geographic atrophy (GA) secondary to <FONT STYLE="white-space:nowrap">age-related</FONT>
macular degeneration and for EMPAVELI<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH) as well as its strategic priorities for continued growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;SYFOVRE is the market-leading treatment for GA, with more than 120% net sales growth year-over-year and more than 510,000 injections administered,&#148;
said Cedric Francois, M.D., Ph.D. &#147;We are entering 2025 with strong momentum and look to build on this by unlocking the blockbuster potential of SYFOVRE in GA and EMPAVELI across multiple rare kidney diseases as well as leveraging our
scientific expertise to drive the next wave of therapeutic innovation. We believe our strategic priorities and strong financials position us for long-term profitable growth.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Transforming the treatment of GA with SYFOVRE </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">More than 510,000 SYFOVRE injections are estimated to have been administered through December 2024, including
clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Distributed approximately 94,000 SYFOVRE doses (commercial and sample vials) to physician practices in 4Q 2025.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prioritizing commercial efforts in the U.S., resulting in plans for incremental reduction of <FONT
STYLE="white-space:nowrap">ex-U.S.</FONT> footprint by approximately 40 employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiation of Phase 1b/2 multi-dose study of <FONT STYLE="white-space:nowrap">APL-3007</FONT> (siRNA) + SYFOVRE
expected in 2Q 2025; potential next generation treatment aimed at comprehensively blocking complement activity in the retina and choroid. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g885806g33r93.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Maximizing EMPAVELI&#146;s impact in rare diseases through leadership in nephrology </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission of a supplemental new drug application (sNDA) expected in early 2025 for C3G and primary <FONT
STYLE="white-space:nowrap">IC-MPGN,</FONT> two rare kidney diseases; U.S. commercial launch planned in 2H 2025, if approved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiation of two Phase 3 studies planned for 2H 2025, one in focal segmental glomerulosclerosis (FSGS) and one
in delayed graft function (DGF), which are rare kidney diseases with high unmet need. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Advancing innovative pipeline, leveraging
complement expertise </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advancing investigational <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research for <FONT
STYLE="white-space:nowrap">one-time</FONT> neonatal Fc receptor (FcRn) treatment using gene editing technology from Beam Therapeutics. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Organizational updates </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Townsend, chief
operating officer, has decided to pursue a new opportunity as a chief executive officer at a private biotechnology company and will depart Apellis on February&nbsp;21, 2025. Since joining Apellis in 2018, Mr.&nbsp;Townsend led the
organization&#146;s transition to a commercial-stage company and built a strong foundation for future growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We&#146;d like to extend a huge thank
you to Adam for his many contributions to Apellis,&#148; said Dr.&nbsp;Francois. &#147;Throughout his tenure, Adam has established a world-class commercial organization, and in his most recent position, he played a key role in the company&#146;s
success due to his extraordinary leadership across commercial and medical affairs. We wish him the best as he embarks on the next chapter of his career.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Acheson, previously the North America senior vice president of commercial, will now serve as the executive vice president of commercial. David joined
Apellis in 2019 and has led the successful U.S. launches of EMPAVELI and SYFOVRE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;David has an impressive history of driving exceptional
results,&#148; said Dr.&nbsp;Francois. &#147;His deep expertise in the U.S. market will be pivotal as we seek to continue SYFOVRE&#146;s growth and execute our strategic expansion into nephrology this year.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, Keli Walbert was recently appointed to the Board of Directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Preliminary full-year 2024 financial results and cash position </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apellis announced preliminary U.S. net product revenues of approximately $709&nbsp;million for the full year
2024.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SYFOVRE: Approximately $167&nbsp;million and $611&nbsp;million expected in preliminary U.S. net product revenues
in the fourth quarter and full year 2024, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EMPAVELI: Approximately $23&nbsp;million and $98&nbsp;million expected in preliminary U.S. net product revenues
in the fourth quarter and full year 2024, respectively. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, Apellis had approximately $410&nbsp;million in
cash and cash equivalents, compared to $351.2&nbsp;million in cash and cash equivalents as of December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apellis anticipates its cash,
combined with expected product revenues, will be sufficient to fund its projected operating expenses and capital expenditures to profitability. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The revenue figures presented in this press release are preliminary and based on management&#146;s estimate as
of the date of this press release and are subject to completion of the Company&#146;s financial closing and review procedures. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g885806g33r93.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>J.P. Morgan Healthcare Conference Presentation and Webcast </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Francois will discuss these updates in a corporate presentation at the 43<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Annual J.P. Morgan
Healthcare Conference today, Monday, January&nbsp;13, 2025, at 9:45 a.m. PT (12:45 p.m. ET). The event will be available via a live webcast from the &#147;Events and Presentations&#148; page of the &#147;Investors and Media&#148; section of the
company&#146;s website. A replay of the webcast will be available for approximately 30 days following the event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About SYFOVRE<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;(pegcetacoplan injection) </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYFOVRE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;(pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy
(GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body&#146;s immune system. SYFOVRE is approved in the United States for the treatment of GA secondary to <FONT
STYLE="white-space:nowrap">age-related</FONT> macular degeneration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About
EMPAVELI<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>/Aspaveli<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pegcetacoplan) </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EMPAVELI<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>/Aspaveli<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;(pegcetacoplan) is a
targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body&#146;s immune system, which can lead to the onset and progression of many serious diseases. It is approved for the treatment of paroxysmal
nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally. The therapy is also under investigation for several other rare diseases across nephrology and hematology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>U.S. Important Safety Information for SYFOVRE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pegcetacoplan injection) </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTRAINDICATIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular
inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g.,&nbsp;anaphylaxis, rash, urticaria) have occurred. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WARNINGS AND PRECAUTIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Endophthalmitis and Retinal Detachments </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal
detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without
delay and should be managed appropriately. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Retinal Vasculitis and/or Retinal Vascular Occlusion </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have
been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change
in vision without delay. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Neovascular AMD </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal
neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth
Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intraocular Inflammation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis,
vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increased Intraocular Pressure </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion
of the optic nerve head should be monitored following the injection and managed as needed. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g885806g33r93.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADVERSE REACTIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Most common adverse reactions (incidence &#8805;5%) are ocular discomfort, neovascular <FONT
STYLE="white-space:nowrap">age-related</FONT> macular degeneration, vitreous floaters, conjunctival hemorrhage. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see accompanying
full Prescribing Information for more information </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>U.S. Important Safety Information for
EMPAVELI<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;(pegcetacoplan) </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOXED WARNING: SERIOUS INFECTIONS CAUSED BY
ENCAPSULATED BACTERIA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPAVELI, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria,
such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become
rapidly life-threatening or fatal if not recognized and treated early. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI,
unless the risks of delaying therapy with EMPAVELI outweigh the risks of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria
in patients receiving a complement inhibitor.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patients receiving EMPAVELI are at increased risk for invasive disease caused by encapsulated bacteria, even
if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Because of the risk of serious infections caused by encapsulated bacteria, EMPAVELI is available only through a restricted program under a Risk Evaluation
and Mitigation Strategy (REMS) called the EMPAVELI REMS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTRAINDICATIONS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hypersensitivity to pegcetacoplan or to any of the excipients </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For initiation in patients with unresolved serious infection caused by encapsulated bacteria
including<I>&nbsp;Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae</I>&nbsp;type B </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WARNINGS AND
PRECAUTIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Serious Infections Caused by Encapsulated Bacteria </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EMPAVELI, a complement inhibitor, increases a patient&#146;s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria
including Streptococcus pneumoniae, Neisseria meningitidis (caused by any serogroup, including non-groupable strains), and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both
vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of EMPAVELI treatment is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to administration of the first dose of EMPAVELI, according to the most
current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI. Note that, ACIP recommends an administration schedule in
patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent EMPAVELI therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria
according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. The benefits and risks of treatment </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g885806g33r93.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with EMPAVELI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused
by encapsulated bacteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies
following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate
medical care if these signs and symptoms occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of EMPAVELI in patients who are undergoing
treatment for serious infections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EMPAVELI is available only through a restricted program under a REMS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPAVELI REMS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EMPAVELI is available only through a
restricted program under a REMS called EMPAVELI REMS, because of the risk of serious infections caused by encapsulated bacteria. Notable requirements of the EMPAVELI REMS include the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the EMPAVELI REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risks, signs, and symptoms of serious infections
caused by encapsulated bacteria, provide patients with the REMS educational materials, ensure patients are vaccinated against encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, prescribe antibacterial drug prophylaxis if
patients&#146; vaccine status is not up to date and treatment must be started urgently, and provide instructions to always carry the Patient Safety Card both during treatment, as well as for 2 months following last dose of EMPAVELI. Pharmacies that
dispense EMPAVELI must be certified in the EMPAVELI REMS and must verify prescribers are certified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is available at
www.empavelirems.com or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-888-343-7073.</FONT></FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Infusion-Related Reactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Systemic hypersensitivity
reactions (e.g., facial swelling, rash, urticaria) have occurred in patients treated with EMPAVELI. One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines. If a
severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Monitoring PNH Manifestations after Discontinuation of EMPAVELI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After discontinuing treatment with EMPAVELI, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease
in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues
EMPAVELI for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interference with Laboratory Tests </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be
interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g885806g33r93.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADVERSE REACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most common adverse reactions in patients with PNH (incidence &#8805;10%) were injection site reactions, infections, diarrhea, abdominal pain, respiratory
tract infection, pain in extremity, hypokalemia, fatigue, viral infection, cough, arthralgia, dizziness, headache, and rash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>USE IN SPECIFIC
POPULATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Females of Reproductive Potential </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to
treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full&nbsp;Prescribing Information, including Boxed WARNING regarding serious infections caused by encapsulated bacteria, and&nbsp;Medication Guide.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Apellis</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apellis Pharmaceuticals, Inc.
is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years
and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious
diseases. For more information, please visit&nbsp;http://apellis.com&nbsp;or follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Apellis Forward-Looking
Statement </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that
are not historical facts, may constitute &#147;forward-looking statements&#148; within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include the Company&#146;s plans, strategies and expectations
for its preclinical, clinical and commercial development of its products and product candidates, its expectations regarding the sNDA for pegcetacoplan for the treatment of for C3G and primary <FONT STYLE="white-space:nowrap">IC-MPGN</FONT> and the
potential commercialization thereof, its plans to initiate Phase 3 studies of pegcetacoplan in FSGS and DGF and the Company&#146;s expectations regarding achieving profitability and the timing thereof. The words &#147;anticipate,&#148;
&#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148;
&#147;target,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially
from those indicated by such forward-looking statements as a result of various important factors, including adjustments to the Company&#146;s preliminary revenue figures resulting from, among other things, the completion of financial closing and
review procedures for the quarter and year ended December&nbsp;31, 2024; whether the results of the Company&#146;s clinical trials for EMPAVELI, SYFOVRE, or any of its future products will warrant regulatory submissions to the FDA or equivalent
foreign regulatory agencies; whether pegcetacoplan will receive approval from the FDA or equivalent foreign regulatory agencies for C3G and <FONT STYLE="white-space:nowrap">IC-MPGN</FONT> or any other indication when expected or at all; rate and
degree of market acceptance and clinical utility of EMPAVELI, SYFOVRE and any future products for which we receive marketing approval will impact our commercialization efforts; whether SYFOVRE will receive approval from foreign regulatory agencies
for GA when expected or at all; whether the Company&#146;s clinical trials will be completed when anticipated; whether results obtained in clinical trials will be indicative of results that will be generated in future clinical trials or in the real
world setting; whether the period for which the Company believes that its cash resources will be sufficient to fund its operations; and other factors discussed in the &#147;Risk Factors&#148; section of Apellis&#146; Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> with the Securities and Exchange Commission (SEC) on February&nbsp;27, 2024, in Apellis&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;1, 2024 and
the risks described in other filings that Apellis may make with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g885806g33r93.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact:</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lissa Pavluk</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>media@apellis.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">617.977.6764 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact</B><B>:</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Meredith Kaya&nbsp;<U> </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>meredith.kaya@apellis.com </U>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">617.599.8178&nbsp;<B></B><B></B><B></B> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>apls-20250108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/13/2025 1:14:20 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:apls="http://www.apellis.com/20250108"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.apellis.com/20250108"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apls-20250108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apls-20250108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>apls-20250108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/13/2025 1:14:20 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>apls-20250108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/13/2025 1:14:20 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="apls-20250108.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g885806g33r93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g885806g33r93.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M:LMM)>Z*UTT=W%",R0, ")0.XP<'Z"@#N[CXK^$(+(W":D9VQD0QQ-O)].0
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C'=2QQ_IS?^@K3 ]&I#"@ H * "@ H * "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45415266462016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001492422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  08,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apellis Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-1537290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Fifth Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">977-5700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APLS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ "TDM6I>*NQS     $P(
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MB^$_7G\!4$L! A0#%     @ "TDM6@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  +22U:C]%$A.\
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    (  M)+5J7BKL<P    !,"   +
M      "  5\/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  M)+5H<.&7J/P$
M #P"   /              "  4@0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  +22U:)!Z;HJT   #X 0  &@              @ &T$0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  +22U:99!YDAD!  #/
M P  $P              @ &9$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"  #C$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d885806d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>apls-20250108.xsd</File>
    <File>apls-20250108_lab.xml</File>
    <File>apls-20250108_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d885806d8k.htm">d885806d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d885806d8k.htm": {
   "nsprefix": "apls",
   "nsuri": "http://www.apellis.com/20250108",
   "dts": {
    "schema": {
     "local": [
      "apls-20250108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "apls-20250108_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apls-20250108_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d885806d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-01-08_to_2025-01-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d885806d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-01-08_to_2025-01-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d885806d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.apellis.com//20250108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-005052-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-005052-xbrl.zip
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MNBEFJV/<WO3'O;EJU@W]_ -02P,$%     @ "TDM6N:N'A)9!@  OD,  !4
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M6S<<SUE*T\U$E1%!?*DNP.N/9&.+94UR3W@V6^$-02ZX-@@B89M7@*($9#5
M%7$&N,/6JR"W[]\-Z3,>KO3<3%7WMB1OY_0$L+%QOGO,!==='21*2V'0RLYH
MXK=9)=*R5QP,;XB@/#IGT9EZ.].6QR?)/8-IML(;@C!0-0AB,YN7 %4#=!$T
M?#MHW<BQ=?\8BX4O9$[U(IFEGX/$FFAS;J]+A1HCO#[&?:%@TL-=)SQ6 %T"
M:9701=^&18)U\Q@@7[*0BR47V:V2VU0-SH2OU")E,^%12Z[W2/6*N9U-;IWB
M/@06\K@SL540LHI0E 1=$VE(_@=?AIEYOCF,(;J@,?F\2F9$M)N8:EZOXV$P
MP,W'W<%_JH5+N5:'7!X):.Q^#?1:-8T!ZC187T9JL43O:'YS_#G4UHKTBO ^
M:]PBV!WN1F%<TE4IV*Z%RWVG5@Q#\ P_&"-Q&D7*@"S^N:*,^.W&P2C0ZR@T
M6>)[ MU'H%84%_]"_TVY ;H27#.L=4QG-@SH/\,+(OH3M7DMIOR!/0O\:OI+
MP-Y@QP3]8Q@:\D\E.P)>EP$N0!?"A1W;0!/J=BX0,<_>%%R+&\'O*0M;OK>M
MTW@)P-<9,U'_)!8-?:-N1_SG[^X4.F4UW"'HQ$K3)+3P@S@.-URF0?P77;:_
MT6-6> FC8#9E&H2M2+0Q,*AV- 1Y)5"E,&_>=&>C:0"LO3@^"*4-"A*T 7X[
MIZ_'H$R-\]UC3@]![>@@@9O]/Z^5<3C%[W/K 2C+9MU U$\FQC<+SEK>--S-
MZPG(6@/<?-P%3+,6$IR9.&3J6#=/NNFW"FF;IMU _4/0-"5LPI-DQ8J;,M*6
MUIKDGI!MML(;@ES@;1!$(KBH -LEG"GNL/$JRFV[=\/YEL<TI"EE\T]JQ2UH
M$-NR;,KL">0&$[PNP@7A.C4D?A_EH=1WAK>KEJODMNK;#=L;0?1\$(5%]CB8
M_HJ N+Z[LU\X-"GTA+&%*;XOT@7K?:I(>*LR4*T#>2'(*CF#WK6)*O#/=(**
M_J64*R+<!\"@\S+&H-Z@>1AVXA%'HD:[J\'(RW4Z'QTY:IR25K8<ES<D7*GU
MU,8_F$UI&EO?X]C-ZVMI4V> FX\[+6N,6EB+FD(<E#ID\NYKFD[ZW5K1M&C:
M#=2I"/3W;6\WR8Q;+\&?)/6$J+EU;CCH J=!"(G,0AER:6<J.VBTBJ1MMSC7
MS?-UN%!N29LGNLVY/5\_C49X?0S&=717#_M:6E; >:*[N[Z-UU3+YC$^WSM/
MB)BKJ?E-\(=TH18CRX"U_#9CC42OG_ UV^)[0]T_XVN016*]^&"L+ 1Y)2A*
M(7W&UZ$-PX=\MEZJ.Z[4EOZ]$\4NFO_V!;7G/U!+ P04    "  +22U:^Q2D
MX+ $  !Z*@  %0   &%P;',M,C R-3 Q,#A?<')E+GAM;-6:78_B-A2&[U?:
M_^"F-ZW4$ ),NX.&65%FID)E9A"P;=6;E4D.8-6Q(SL,\.][''!%(,S"=%O%
M7/#A^#U^SWF,24QN/JX33EY :29%QPMK=8^ B&3,Q+SC+;5/=<281W1&14RY
M%-#Q-J"]C[?OW]U\X_OD[J'_1'RRR+)4MX-@M5K5XAD36O)EAB%U+9))0'S?
M]N]-/I'?ML.UR0@X4 TDH3H#17Y>,AZW&_5&*PP;C5JX+U- 33P2TPS:) S"
M9H =KTC8#ELH(<-'<I]'$63"$MB7RG2CV'R1D>^B[TDNNI-" .>P(0],4!$Q
MRLG8.OZ!]$54(UW.R<C(--K4H%X@KNVB<B;^:INGJ3%/WK\C^, Z"IVW=CQ3
MC5TQUE/%:U+-T6V]&5B1MZ]9'XE6S5P27E]?!_G18G_-RGKC &'PQ^-@'"T@
MH3XR0&;1P5#H)L[^4>^;NPJV!VU_S=HZCS2045[Z,](B)WN83[[MYILF/VSX
MS;"VUK%W:X;<5E5)#B.8$?/Z:=0OC$E39,:V,RJ'7P_K'X*,KJ60R28PDN!.
M1LL$1&9?NR*^%QG+-GTQDRK)$_%(7M/V0L&LX]&4:]]&,W:^'6&@SY<$RC8I
M?BTT2U(.'@GVTDD53AV1Y;T'V% 0P#H#$4-LPY@$_IN$;[=,=Q-71H4"V*]N
M#DQ#5)O+ER &9D9LF3>F.JV\,OCA<T_B:M&=ZDS1*"M6@)N9(I5MY'0*O..5
MB(*O::B+:<<F]0=.Y^<:.A 5#>U3ZZJH$)*JR(;#MT?(BK-^UR-(J<)X?K3
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M-\%1:0;88.Z9W!XQ3^8.0&SY&U!+ P04    "  +22U:7U/_ZN@8  #0A
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MW62&(=<^H%%-,<!S>["KZ?:S0V5W2P,Q8R"'B<8OM"@(%C;(A*N,E[2A%=(
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M0?T>/$L)AP/ER 8:0X&BHS7M)[?ZR;*U!_%()</1O*R..6;ZE,+DG4+- RG
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M">LE(/S7/-SP:QF^;_/R'&,>SW/DE1LOQPU;K)OFT%RQ;IT@X*C65_X$/D,
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M%<"K\&NXKMV#:D5QX)HGPD_@M,X2H&>1!(RY:IPV:H!(\ _3._@J&-KOR<F
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M&1T-#@K'D_ H\764@*.W&9_DE,5X)'SR3O!^G\M$D<_P 38$8XVT^Q/VB&@
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MOR:'26_#)C+5<$%[^^_>,]X8-5CGCJUO;>.?,?[9NMMHH.>!(2DJS#5\S&5
M*0)CR6&K 9J/'LR-D,L"MZ@-0:VQ%C?@SMQ+5,;^@MAIJ8?^H$V^FRC1WUP)
M7W)K<1*>0VRT7]"A-K  )5/18$T@,6ABM>/:E<TNG[)]2D+8SB80P0F&-@9!
M]&!S$&C[2Z6BY_2,]M >[:9L?4\-+">Y2=_TXLRMU\*=/YU]]MA&3$937R8J
MK:/C.(_A,*DSDP59:M4*IJDUV/&$I;!)00+B":"&DROE"P5K,GXD&!3DDW+
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M'!9V>&U.,39J165;ECI%5S'3?_F8Z>;IE]9MM\5N6\V3E4]ZQ29G"-T5EI[
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M)KKF6MH%DSW)[Z7EWLNQU6%>,_/Y*183;H'.)@F#4$/%2G7-)J1M!OAJ,Y:
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M1+KZ?#YGM6([*%!U-;ED1!*?*)\6'J#I"4F;@:GBJ!NL.[/OPGO%GLEY=6(
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MZFYD^+*N6Y\6U<[(%4"%RXJX?VEZ0"CT&1B+JH[:'Z).K%_-Z\$7+AE8&+6
MSM10)(4M25OML#FZ[FZM^QY;)SEY0-  !V]OO:=6>TK'R&(G9=+\TX>H**5O
MWU>EIAI%UHYCZBTZ=BQOU($105CLG]SWUCS="V3H(QL!YH*MS'6S%VS237OL
MB4 *:DQCK!-H'N^)04:GFX5!Y-UK8VY.*/ DG27;0OIN!P&RT9D6 F=STOV
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MVT6_W]MK[&Y]W#5;/SXRI^_\LX2BPL\WI[_"PXN[J\NC_P=02P$"% ,4
M"  +22U:JG%:E#D#  !)"P  $0              @ $     87!L<RTR,#(U
M,#$P."YX<V102P$"% ,4    "  +22U:YJX>$ED&  "^0P  %0
M    @ %H P  87!L<RTR,#(U,#$P.%]L86(N>&UL4$L! A0#%     @ "TDM
M6OL4I."P!   >BH  !4              ( !] D  &%P;',M,C R-3 Q,#A?
M<')E+GAM;%!+ 0(4 Q0    (  M)+5I?4__JZ!@  -"$   .
M  "  =<.  !D.#@U.# V9#AK+FAT;5!+ 0(4 Q0    (  M)+5JU^/6"@"0
M %7'   1              "  >LG  !D.#@U.# V9&5X.3DQ+FAT;5!+!08
1    !0 % $ !  ":3      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d885806d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="apls-20250108.xsd" xlink:type="simple"/>
    <context id="duration_2025-01-08_to_2025-01-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492422</identifier>
        </entity>
        <period>
            <startDate>2025-01-08</startDate>
            <endDate>2025-01-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-280">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-01-08_to_2025-01-08"
      id="Hidden_dei_EntityCentralIndexKey">0001492422</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-291">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-292">2025-01-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-293">Apellis Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-294">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-295">001-38276</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-296">27-1537290</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-297">100 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-298">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-299">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-300">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-301">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-302">977-5700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-303">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-304">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-305">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-306">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-307">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-308">APLS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-309">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-01-08_to_2025-01-08" id="ixv-310">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
